Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses tamoxifen as breast cancer prevention
Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses tamoxifen as breast cancer prevention.
Muss says breast cancer prevention is difficult. Many of the studies that have looked at tamoxifen or aromatase inhibitors as breast cancer prevention have shown that these agents prevent breast cancer, but don’t save any lives. What these studies show is that many of the people that develop breast cancer were able to survive the disease, Muss says.
Muss says the decision to use prevention depends on the patient’s average risk. Understanding the patient’s risk can help determine the potential benefits of these prevention drugs since these drugs come with side effects.
These breast cancer prevention drugs provide the most benefit to premenopausal younger patients or older women who have had a hysterectomy, Muss says.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.